Home > News > BioAlliance Pharma Announces Preliminary Results
June 30th, 2006
BioAlliance Pharma Announces Preliminary Results
Abstract:
BioAlliance Pharma SA (Paris:BIO) announced today the presentation of preliminary results from its Doxorubicin Transdrug(R) Phase I/II clinical trial for primary liver cancer. "These results are also extremely positive because of their encouraging implications for the future application of our Transdrug(R) nanotechnology platform."
Source:
businesswire
Bookmark:
| Related News Press |
Possible Futures
Spinel-type sulfide semiconductors to operate the next-generation LEDs and solar cells For solar-cell absorbers and green-LED source October 3rd, 2025
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Rice membrane extracts lithium from brines with greater speed, less waste October 3rd, 2025
Researchers develop molecular qubits that communicate at telecom frequencies October 3rd, 2025
Next-generation quantum communication October 3rd, 2025
"Nanoreactor" cage uses visible light for catalytic and ultra-selective cross-cycloadditions October 3rd, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||